top of page

Pepticom creates new spinoff, PeptiCov, to Focus on COVID

'Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus on treatments for the SARS-Cov-2 virus, responsible for the COVID-19 outbreak. The company, PeptiCov, will implement Pepticom's AI technology to design, discover and develop novel peptide molecules for effective treatment of the SARS-Cov-2 virus. The funding round was led by the Chartered Group...

010921 Pepticom's New Spinout Company, P
Download • 162KB

bottom of page